Zidovudine

• 

  Subject Areas on Research

  • 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. 
  • 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. 
  • A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. 
  • A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. 
  • A phase I/II study of the protease inhibitor indinavir in children with HIV infection. 
  • A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. 
  • A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. 
  • A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. 
  • A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. 
  • A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. 
  • AZT inhibits HIV-1 replication in monocytes. 
  • Acyclovir in human immunodeficiency virus patients. 
  • Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. 
  • Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. 
  • Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. 
  • Antiviral therapy for human immunodeficiency virus infection in children. 
  • Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. 
  • CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. 
  • Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. 
  • Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. 
  • Chronic multifocal retinal infiltrates in patients infected with human immunodeficiency virus. 
  • Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. 
  • Conjugates of betulin derivatives with AZT as potent anti-HIV agents. 
  • Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. 
  • Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. 
  • Cost effectiveness of treating asymptomatic HIV infection. 
  • Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. 
  • Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. 
  • Current and future treatment of HIV infection. 
  • DNA polymerases versus HIV reverse transcriptase in AIDS therapy. 
  • Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. 
  • Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection. 
  • Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group. 
  • Derivation of a biologically contained replication system for human immunodeficiency virus type 1. 
  • Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro. 
  • Disorders of the nails and hair associated with human immunodeficiency virus infection. 
  • Early cardiac dysfunction in children and young adults with perinatally acquired HIV. 
  • Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. 
  • Early zidovudine and survival in HIV infection. 
  • Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. 
  • Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. 
  • Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. 
  • Ethical dilemma in continuing a zidovudine-placebo trial in symptomatic human immunodeficiency virus infection. 
  • Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. 
  • Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. 
  • Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1. 
  • Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. 
  • Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group. 
  • HIV therapeutics: an emerging science. 
  • HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. 
  • HIV-1 sensitivity to zidovudine and clinical outcome in children. 
  • HIV-1 sensitivity to zidovudine and clinical outcome. 
  • HIV-associated autoimmune hemolytic anemia: report of a case and review of the literature. 
  • How do North Carolina prenatal care providers counsel and test pregnant women for HIV? Survey measures knowledge of HIV testing benefits. 
  • How much zidovudine is safe for children with advanced HIV? 
  • Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • Inhibition of HIV-1 proviral DNA synthesis and RNA accumulation by mismatched dsRNA. 
  • Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. 
  • Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. 
  • Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). 
  • Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. 
  • Late treatment of HIV infection--is it better? 
  • Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. 
  • Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. 
  • Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. 
  • Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. 
  • Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. 
  • Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy. 
  • Neurobehavioral assessment of mice after developmental AZT exposure. 
  • Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. 
  • On assessing bioequivalence and interchangeability between generics based on indirect comparisons. 
  • One-pot synthesis of an AZT boranophosphate conjugated with tyrosine: a potential prodrug candidate. 
  • Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. 
  • Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. 
  • Pharmacokinetics and tolerance of zidovudine in preterm infants. 
  • Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. 
  • Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. 
  • Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. 
  • Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. 
  • Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. 
  • Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy. 
  • Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. 
  • Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. 
  • Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. 
  • Seizure associated with zidovudine. 
  • Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. 
  • Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. 
  • Systemic antiviral drugs used in ophthalmology. 
  • Taste and smell complaints in HIV-infected patients. 
  • Taste and smell losses in HIV infected patients. 
  • The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. 
  • The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. 
  • The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. 
  • The effect of zidovudine on patient subgroups. 
  • The effects on survival of early treatment of human immunodeficiency virus infection. 
  • The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. 
  • Therapeutic effects of diethylcarbamazine and 3'-azido-3'-deoxythymidine on feline leukemia virus lymphoma formation. 
  • Transmission of HIV by antigen presenting cells during T-cell activation: prevention by 3'-azido-3'-deoxythymidine. 
  • Treatment of children symptomatic with human immunodeficiency virus infection. 
  • Treatment of mildly symptomatic human immunodeficiency virus (HIV) infection. 
  • Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. 
  • Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. 
  • Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. 
  • Zidovudine and the natural history of AIDS. 
  • Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. 
  • Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group. 
  • Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 
  • Zidovudine-induced neutropenia: are we too cautious? 
• 

  Keywords of People

  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology